Wells sees potential upside after Glaukos’ iDose repeat dosing label approved

Wells Fargo notes that Glaukos (GKOS) has announced FDA support of its repetition dosing statement for iDose, successful enactment with the firm’s expectations. Label appears wide though with immoderate corneal-safety limits. Overall, Wells views this arsenic supportive of the semipermanent iDose annuity model. The steadfast has an Overweight standing connected the shares with a price target of $122.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected GKOS:

Disclaimer & DisclosureReport an Issue

• Glaukos announces FDA support of iDose TR NDA labeling supplement

• Glaukos terms people raised to $160 from $115 astatine Stifel

• Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS successful Focus for Investors

• Glaukos falls -8.5%

• Video: Wells Fargo dips arsenic large slope net continue